About the Conference

The inaugural PharmaConnect Africa Conference and Expo was held on the 29th and 30th of March 2017. Over the years, PharmaConnect Africa has been considered a credible forum where roleplayers in Africa pharma can meet and network. Our conferences have included official representation from regulators (e.g. Ghana FDA, East Africa Community (EAC) and the home authority (South African Health Products Regulatory Authority), Department of Health (South Africa), local manufacturers (NAPM and SAGMA), innovator companies and associations under the auspices of Innovative Pharmaceutical Association of South Africa (IPASA), various South African universities, USP Convention, UN agencies (UNIDO and WHO), and SADC-aligned business forum (SABF).

Pharmaconnect Africa Conferences aim to bring all role players in the pharmaceutical and healthcare industry in Africa together to discuss a common agenda. They address issues in four focal areas in order to create continuity of solutions from year to year. These areas are clustered into 4 thematic sessions addressing key issues in the pharmaceutical and healthcare industries in Africa i.e. Clinical Trials, Regulatory harmonization, Education and Training, and Local Pharmaceutical Production.  They all aim to enhance access to essential medicines and health products for Africa and her citizens as defined by the World Health Organization (WHO). Essential medicines and health products are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality, and at a price, the individual and the community can afford.

Pharmaconnect Africa 2019 will build on the success of previous conference, and bring exciting panelists who are knowledgeable of the global and African pharmaceutical and healthcare landscape. It will provide an important networking platform for your organization.

Scientific Review Committee (SRC)

Prof David R Katerere [Ph.D.] – Tshwane University of Technology – SRC Chair

With a PhD in Pharmaceutical Science from Strathclyde (Glasgow), David previously worked at Farmovs-Parexel CRO Pty Ltd and then South African Medical Research Council (SAMRC). He was also a visiting scientist at Scynexis Inc, RTP, North Carolina in 2010. His areas of interest and expertise are natural products/pharmacognosy, analytical chemistry, and regulatory science. He is on the advisory committees of  SAHPRA has completed several consulting assignments for Department of Trade and Industry, SADC as well as United Nations Industrial Development Organization (UNIDO).

Dr. Judy Coates [Ph.D.] – Executive Director, Pharmaceutical Society South Africa, Southern Gauteng (PSSA SG).

Judy has been in the Pharmaceutical industry for fifteen years, initially specializing in research and development and thereafter progressing into investment and now government and regulatory affairs. Her career began with joining Mintek in 2003 after obtaining her PhD in Organic Chemistry at the University of Johannesburg (RAU). Judy started her research career looking at the synthesis and biological activity of a variety of metal-based phosphine compounds in a secondment to University of Witwatersrand. Judy served as the head of the Biomedical Group at Mintek for a period of eight years. In July 2011 Judy transferred from Head: Biomed to the Human Resources Division in the position of Head: Academic Support. At the end of 2012 Judy joined the Technology Innovation Agency (TIA), an entity of the Department of Science and Technology, in Pretoria as the General Manager: Health. From TIA Judy moved to the Innovative Pharmaceutical Association South Africa (IPASA), appointed as the Scientific and Regulatory Affairs Manager.  Here she was responsible for monitoring trends, issues, problems, opportunities and activities in the healthcare environment, with a specific focus on Scientific and Regulatory Affairs, in order to identify legislative issues that can affect the industry; developing IPASA positions on key issues in conjunction with members; and the overall coordination and support of a number of the IPASA Working Groups. In addition to her employment at PSSA Judy currently serves on the TIA Board, The Innovation Hub’s BioPark Steering Committee, SARIMA’s Technology Transfer Mentorship Programme, and the NECSA (NTeMBI & NuMeRI) Review Panels.

Dr. Mbali Keele [Ph.D.] – Moteli Consultants

Worked as a lecturer at the Department of Pharmacy of the Nelson Mandela Metropolitan University (NMMU) for eight years. More recently she was at the National Department of Health as a Medicines Research Officer within the Medicines Evaluation and Research (ME&R) Directorate, supporting the work of the Medicines Control Council. She rose to the rank of Acting Deputy Director of the Pre-registration Unit at the ME&R before leaving to join one of the largest pharmaceutical companies in South Africa within its Regulatory Affairs Unit. She has extensive knowledge in product formulation and medicine registration.

Dr Clinton Rambanapasi [PhD] – Roche Products (Pty) Ltd

Completed his Bachelor of Pharmacy (Honours) degree in 2006 at the University of Zimbabwe, Master of Science in Medical Pharmaceutical Sciences in 2010 from the University of Groningen and PhD in Pharmaceutics at the North-West University, Potchefstroom campus in 2016.

Clinton has amassed extensive experience in the pharmaceutical sector in Sub Saharan Africa as a pharmacist and pharmaceutical scientist since graduating in 2006. He started his career in Regulatory Affairs in 2007 at Medicines Control Authority of Zimbabwe. Post his masters degree he had short stints at the MCAZ, a contract research organization as a clinical trials pharmacist and lecturer in Pharmaceutics at the University of Zimbabwe. In 2012 he joined the PreClinical Drug Development Platform in the School of Pharmacy at NWU for his PhD where he worked on assessing the in vivo toxicity of a nano-gold (a proposed drug delivery system). After his PhD he joined Rhodes University, Faculty of Pharmacy as a lecturer and eventually left to join Roche. Currently he is a senior regulatory affairs pharmacist at Roche responsible for the SADC countries. He has a strong interest in regulatory science as a discipline and regulatory policy topics.